RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Regulatory Manager: What Senior Management Needs to Know About CMC Regulatory Compliance for Biotec

Regulatory Manager: What Senior Management Needs to Know About CMC Regulatory Compliance for Biotech Products Part 3: Submission of the Marketing Application

Posted 01 October 2009

The completion of Phase 3 clinical trials, along with completing the definition of the manufacturing process and product, is a major milestone for a biotech company. Activities now focus on preparing the appropriate marketing application for the US Food and Drug Administration (FDA) (the New Drug Application (NDA) for biotech hormones and the Biologics License Application (BLA) for all other biotech products) and/or for the European Medicines Agency (EMEA), which uses the Marketing Authorization Application (MAA) for all biotech products. The goal of this submission from a CMC perspective is to provide enough information to permit the respective regulatory authority to determine whether the methods used in manufacturing the biotech drug and the controls used to maintain its quality are appropriate and adequate to ensure the drug's identity, strength, quality, purity and safety.

 

© 2022 Regulatory Affairs Professionals Society.